Global Behcet Disease Pipeline Review, H2 2018 Featuring AbbVie, Celgene, Coherus BioSciences, Novartis & R Pharm - ResearchAndMarkets.com
The "Behcet Disease - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Behcet Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Behcet Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Behcet Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Behcet Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 1, 1, 1, 2 and 1 respectively.
Behcet Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Report Coverage
- Behcet Disease - Overview
- Behcet Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Behcet Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Behcet Disease - Companies Involved in Therapeutics Development
- AbbVie Inc
- Celgene Corp
- Coherus BioSciences Inc
- Novartis AG
- R Pharm
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/bh6l84/global_behcet?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005636/en/